. 2019 Feb 14;47(4):1610–1619. doi: 10.1177/0300060518825428

Table 1.

Patient demographics and outcomes.

Variable	CE^a (n = 184)	UN^a (n = 182)	p-value
Sex, No. male/female	70/114	64/118	0.568*^,b
Age (years)	71.3 ± 8.2	71.7 ± 7.8	0.105*^,c
Body mass index (kg/m²)	27.4 ± 8.0	26.8 ± 9.5	0.139*^,c
Bone mineral density	−3.8 ± 0.3	−3.8 ± 0.5	0.154*^,c
Side, No. left/right	87/97	83/99	0.748*^,b
Comorbidities			0.935*^,d
Hypertension	43	47
Diabetes mellitus	32	37
Hyperlipidemia	54	58
Underlying diagnoses for primary total hip arthroplasty			0.872*^,d
Osteoarthritis	44	46
Posttraumatic arthritis	32	27
Femoral neck fractures	40	41
Avascular necrosis	40	36
Rheumatoid arthritis	28	32
Sequela of developmental hip dysplasia	8	10
ASA Index			0.892*^,d
1	45	40
2	86	92
3	53	50
Preoperative Harris Hip Score	55.2 ± 12.7	54.8 ± 11.6	0.103*^,c
Follow-up period (months)	75.3 ± 9.7	75.7 ± 10.4	0.087*^,c

*Not statistically significant.

^aStryker Corporation, Kalamazoo, MI, USA; ^bAnalyzed using the chi-squared test; ^cAnalyzed using an independent-samples t-test; ^dAnalyzed using the Mann-Whitney test. UN: uncemented; CE: cemented; ASA: American Society of Anesthesiologists.